Fri, Aug 22, 2014, 6:12 AM EDT - U.S. Markets open in 3 hrs 18 mins

Recent

% | $
Quotes you view appear here for quick access.

EDAP TMS SA Message Board

  • dayfornight1973 dayfornight1973 Oct 15, 2006 1:01 AM Flag

    EDAP

    I think what intrigues me most about EDAP and HIFU is the potential treatment of other forms of cancer besides prostate cancer. With ten years of European data and now the U.S. clinical trials underway, this company provides a quality investment at a relatively good price. So far, all the news has been fairly positive. I think we'll see $20 + again soon. Of course, with FDA approval, the sky's the limit. Does anyone know when we can expect to hear some results from the U.S. clinical trials?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Not sure about in the States but with all the publicity, conventions, patients and families and medical professionals connected with EDAP now it's nice to see a European weigh in here. There's only a seven million share or so float. Good luck my friend.

    • The FDA moves slowly and I personally do not expect approval until a year or so.

      Go to www.clinical trials.gov and look up ablatherm. Tests aRE underway at Duke, Baylor etc.--and when the USA catches up with the rest of the world this WILL be approved. It is currently being used in Europe, China, Canada etc. Pull up HIFU under www.Google.com.

      Look at the hole page for EDAP.

      As a prostate cancer survivor I had surgery. However, some can not have surgery because of health reasons and HIFU is an alternative.

      Prostate problems are not "fun" but a fact of life which an aging population will have to face.

      Best wishes! IAM A FIRM BELIEVER IN EDAP FOR THE LONG TERM> Day traders will not like this stock.

 
EDAP
1.73-0.02(-1.14%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.